Truist Securities Maintains Hold on Cross Country Healthcare, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Tobey Sommer has maintained a Hold rating on Cross Country Healthcare (CCRN) and reduced the price target from $22 to $16.
February 22, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities maintains a Hold rating on Cross Country Healthcare and lowers the price target from $22 to $16.
The reduction in the price target from $22 to $16 by a reputable analyst firm like Truist Securities could lead to a negative perception among investors, potentially causing a short-term decrease in the stock price. The Hold rating remains unchanged, indicating that the firm does not see significant upside or downside from the current level, but the lowered price target suggests a recalibration of expected performance, which could influence investor sentiment negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100